Table 2 Baseline characteristics after propensity score matching
Variable | R group | L group | P value |
|---|---|---|---|
n = 354 | n = 177 | ||
Sex (male) | 290 (81.9%) | 146 (82.5%) | 0.968 |
Poor differentiation | 152 (42.9%) | 76 (42.9%) | 0.882 |
Lymphatic metastasis | 2 (0.6%) | 2 (1.1%) | 0.859 |
Cirrhosis | 248 (70.1%) | 121 (68.4%) | 0.764 |
MVI | 133 (37.6%) | 75 (42.4%) | 0.330 |
Satellite nodules | 42 (11.9%) | 24 (13.6%) | 0.676 |
Tumor number (single) | 319 (90.1%) | 154 (87.0%) | 0.392 |
GVI | 34 (9.6%) | 18 (10.2%) | 0.959 |
Invading adjacent organs | 0 (0.0%) | 0 (0.0%) | 1.000 |
Positive HBsAg | 305 (86.2%) | 151 (85.3%) | 0.895 |
Positive HBeAg | 72 (20.3%) | 38 (21.5%) | 0.850 |
AFP (< 400 ng/mL) | 205 (57.9%) | 98 (55.4%) | 0.642 |
Age (year) (IQR) | 49.0 (41.0–59.0) | 49 (41.0–58.0) | 0.510 |
Tumor diameter (cm) (IQR) | 5.0 (3.5–8.0) | 5.0 (3.5–8.0) | 0.743 |
NEU count (109/L) (IQR) | 3.12 (2.42–4.13) | 2.99 (2.39–4.09) | 0.684 |
LYM count (109/L) (IQR) | 1.41 (1.11–1.77) | 1.44 (1.05–1.83) | 0.983 |
PLA count (109/L) (IQR) | 122.0 (84.0–173.0) | 128.0 (88.5–170.0) | 0.617 |
TBIL level (mmol/L) (IQR) | 14.00 (10.60–17.83) | 13.40 (10.15–17.75) | 0.348 |
ALT level (U/L) (IQR) | 40.00 (26.75–57.25) | 39.00 (26.00–57.00) | 0.618 |
AST level (U/L) (IQR) | 38.00 (29.00–54.00) | 38.00 (29.00–52.00) | 0.695 |
ALB g/dL | 41.70 (39.00–44.90) | 41.60 (39.10–41.60) | 0.562 |
BCLC | |||
0 | 175 (49.4%) | 86 (48.6%) | 0.780 |
A | 118 (33.3%) | 55 (31.1%) | |
B | 29 (8.2%) | 19 (10.7%) | |
C | 32 (9.0%) | 17 (9.6%) | |